14521-96-1

Usage

Chemical Properties

White, crystalline powder

Uses

Etorphine is used as a narcotic analgesic.

InChI:InChI=1/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1

Upstream product

• 467-04-9 oripavine 
• 2234-82-4 1-propylmagnesium chloride 
• 76-57-3 codeine 
• 60342-45-2 N-(ethoxycarbonyl)norcodeinone 
• 36397-12-3 N-desmethyl-N-carboethoxycodeine 
• 757950-17-7 N-carboethoxythebaine 
• 15358-22-2 thevinone 
• 115-37-7 thebaine 
• 16180-26-0 etorphine methyl ether 

Downstream Products

• 25333-77-1 3-acetoxy-4,5α-epoxy-19anti-((R)-1-hydroxy-1-methyl-butyl)-6-methoxy-17-methyl-6β,14-ethano-morphin-7-ene 
• 26626-23-3 (R)-2-(4,5α-epoxy-6-methoxy-17-methyl-6α,14α-etheno-morphinan-7α-yl)-pentan-2-ol 
• 92264-44-3 S-etorphine 
• 14357-76-7 Dihydroetorphine 

Relevant academic research and scientific papers

IMPROVED METHOD OF MANUFACTURING BUPRENORPHINE AND ANALOGUES THEREOF FROM ORIPAVINE

The invention relates to an improved method of preparing buprenorphine, a salt thereof, analogues of buprenorphine and their salts. In particular, the invention relates to a method of preparing buprenorphine and related products and salts in economic and ecologic ways having increased yields.

A facile synthesis and structural verification of etorphine and dihydroetorphine from codeine

In this study, an improved process for the synthesis of etorphine and dihydroetorphine from codeine with an overall yield of 2.7% and 1.5% respectively is described. The structure of 19-propylthevinol 7 was verfied by X-ray structure analysis. This result is promising for synthesizing various morphine-based drugs.

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

(+)-Isomers of endoetheno/endoethano-epoxymorphinan derivatives as antitussive agents

A class of epoxymorphinan derivatives is described having use as antitussive agents. Compounds of this class are character-ized in having antitussive potency but lacking narcotic side effects. Compounds of interest are those of the formula wherein R1 is selected from hydroxy, alkylcarboxyl, alkoxy and phenoxy; wherein R2 is selected from hydrido, alkyl, acyl and phenyl; wherein R3 is selected from wherein each of R5, R6, R7 and R8 is independently selected form hydrido, alkyl, phenyl and phenalkyl, wherein R4 is selected from hydrido, alkyl, cyano, cycloalkyl, cycloalkylalkyl, cycloalkyl-carbonyl, allyl, phenyl, benzyl, phenethyl and phenpropyl; and wherein any of the foregoing R1, R2, R3, R4, R5, R6, R7 and R8 substituents having a substitutable position may be substituted with one or more groups selected from hydroxy, halo, alkyl and cycloalkyl; or a pharmaceutically-acceptable salt thereof.